Compare Abeona Therapeutics Inc (ABEO) vs Kroger Co (KR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs Kroger Co — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $424.33M), while Kroger Co trades at $56.21 (market cap $34.60B). The key difference: Kroger Co is far larger — about 81.5× Abeona Therapeutics Inc's market cap, and Kroger Co pays a 2.55% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | KR | |
|---|---|---|
Market Cap | $424.33M | $34.60B |
Sector | Health | Consumer Staples |
52-Week High | $7.45 | $75.60 |
52-Week Low | $4.17 | $55.53 |
Enterprise Value | $279.23M | $54.70B |
Dividend Yield | — | 2.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.24, up 4.93% today, with bullish technical signals from moving averages. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent developments include CMS granting NTAP status for ZEVASKYN and expansion to seven treatment centers, while Q2 2026 earnings are scheduled for August 13, 2026.
Strong analyst support (66.7% buy ratings) and attractive valuation metrics (P/E 7.84, EV/EBITDA 3.8) support upside potential, but negative operating cash flow and shareholder investigation pose near-term risks. The stock's outlook depends on commercial execution and Q2 earnings results.
Kroger (KR) trades at $56.73, down 1.03% with bearish technical signals from moving averages. The company maintains stable revenue around $147B with recent earnings showing mixed results - beating estimates in Q3 and Q4 2025 but missing in Q1 2026. Kroger demonstrates strong cash flow generation with $5.8B from operations in 2025 and pays consistent dividends, while expanding digital services and AI shopping assistance.
Kroger presents a defensive investment opportunity with 2.7% dividend yield and analyst consensus target of $68.63 (21% upside). However, rising debt levels and competitive pressures in grocery retail pose risks. The stock offers value with P/S of 0.25x but trades at premium P/E of 33x, requiring earnings acceleration to justify valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →
